logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation

BlueFocus Intelligent Communications Group (300058.SZ) issued a total of 80 million restricted stocks at a grant price of 4.33 per share to 244 incentive recipients.

date
18:41 07/09/2023
avatar
GMT Eight
BlueFocus Intelligent Communications Group (300058.SZ) announced that the granting conditions of the company's incentive plan have been fulfilled. It has been agreed to set the grant date as September 7, 2023. A total of 80 million restricted stocks will be granted to 244 eligible incentive recipients, at a grant price of 4.33 yuan per share.
Related Articles
New stock news | Capital (601136.SH) submits a second application to the Hong Kong Stock Exchange, with total revenue exceeding 3.6 billion yuan in 2025.
China Stock
Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.
China Stock
Shenghe Jingwei (688820.SH) stock will be listed on the Science and Technology Innovation Board on April 21st.
New stock news | Capital (601136.SH) submits a second application to the Hong Kong Stock Exchange, with total revenue exceeding 3.6 billion yuan in 2025.
Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.
China Stock
Shenghe Jingwei (688820.SH) stock will be listed on the Science and Technology Innovation Board on April 21st.
China Stock
RECOMMEND
Hong Kong Hard‑Tech Companies Enhance Canton Fair Presence As Veterans And Newcomers Expand International Networks
Hong Kong Hard‑Tech Companies Enhance Canton Fair Presence As Veterans And Newcomers Expand International Networks
icon
17/04/2026
Thousand‑Fold Oversubscription In Hong Kong IPOs Signals Multiple Market Shifts
Thousand‑Fold Oversubscription In Hong Kong IPOs Signals Multiple Market Shifts
icon
17/04/2026
Rising Compute Costs Drive Industry Price Increases As Institutions Expect Internet Firms To Outperform In Q1
Rising Compute Costs Drive Industry Price Increases As Institutions Expect Internet Firms To Outperform In Q1
icon
17/04/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.